Pharmaceutical Investing Innovation Pharmaceuticals Signs Drug Supply Contract with Evonik to Bulk Produce Commercial-Grade Brilacidin
Pharmaceutical Investing Innovation Pharmaceuticals Data from Phase 2 Brilacidin Oral Mucositis (OM) Trial in Head and Neck Cancer Show Notable Reductions in Median Duration of Severe OM
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
Sucampo Reports Top-Line Data from Phase 2a Study of Cobiprostone in Patients with PPI-Refractory Non-Erosive Reflux Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease (sGERD)
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
